Genmab raises guidance ahead of annual report
Sales of the Genmab-developed cancer drug Darzalex have been so strong throughout 2016 that the biotech is raising its financial guidance for 2016 just a few weeks before the publication of the annual report.
BY LOUISE WENDT JENSEN
Sales percentages from Janssen’s net sales of multiple myeloma drug Darzalex have surpassed Genmab’s expectations, and the Danish biotech is thus raising its financial guidance a few weeks before it is scheduled to publish its annual report for 2016.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab digs deeper in its goldmine
For abonnenter
Genmab earns another USD 25 million from Darzalex sales
For abonnenter
